scholarly journals Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity 131I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-up

2013 ◽  
Vol 98 (7) ◽  
pp. 2693-2700 ◽  
Author(s):  
Eleonora Molinaro ◽  
Carlotta Giani ◽  
Laura Agate ◽  
Agnese Biagini ◽  
Letizia Pieruzzi ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Hormone ◽  
Hormone Therapy ◽  
Differentiated Thyroid Cancer ◽  
Thyroid Remnant ◽  
Remnant Ablation ◽  
Recombinant Human Tsh ◽  
Therapy Withdrawal ◽  
Low Activity

scholarly journals Thyroid Hormone Supplementation Therapy for Differentiated Thyroid Cancer After Lobectomy: 5 Years of Follow-Up

2020 ◽  
Vol 11 ◽  
Author(s):  
Soo Young Kim ◽  
Hee Jun Kim ◽  
Seok-Mo Kim ◽  
Hojin Chang ◽  
Yong Sang Lee ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Hormone ◽  
Differentiated Thyroid Cancer

The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre

2002 ◽  
Vol 56 (2) ◽  
pp. 247-252 ◽  
Author(s):  
Vitale Giovanni ◽  
Lupoli Gelsy Arianna ◽  
Ciccarelli Antonio ◽  
Fonderico Francesco ◽  
Klain Michele ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Single Centre ◽  
Patient Cohort ◽  
Large Patient Cohort ◽  
Recombinant Human Tsh ◽  
Large Patient ◽  
Cancer Experience

Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients

2015 ◽  
Vol 54 (03) ◽  
pp. 137-143 ◽  
Author(s):  
A.-S. Moldovan ◽  
M. Ruhlmann ◽  
R. Görges ◽  
A. Bockisch ◽  
S. Rosenbaum-Krumme ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Absorbed Dose ◽  
Thyroid Remnant ◽  
Remnant Ablation ◽  
Dose Threshold ◽  
131I Activity ◽  
Pet Ct ◽  
Absorbed Radiation Dose

SummaryAim: A theoretical dosimetry-based model was applied to estimate the lowest effective radioiodine activity for thyroid remnant ablation of low-risk differentiated thyroid cancer patients. Patients, methods: The model is based on the distribution of the absorbed (radiation) dose per administered radioiodine activity and the absorbed dose threshold of 300 Gy for thyroid remnants, the level believed to destroy most thyroid remnants. For this purpose, 124I PET/CT images of 49 thyroid-ectomised patients were retrospectively analysed to measure the distribution of the (average) absorbed doses to thyroid remnant per administered 131I activity. The fraction of thyroid remnants that received at least 300 Gy was determined for standard activities between 0.37 and 5.55 GBq. The lower activity was considered to be equally effective to that obtained with higher activity if the (absolute) fraction difference was below 5%. Results: A total of 62 thyroid remnants were included. The medians and ranges (in parentheses) for the absorbed dose per unit 131I activity were 359 Gy/GBq (34 to 1825 Gy/ GBq). The fractions of thyroid remnants receiving more than 300 Gy at different therapy activities (within parentheses) were 60% (1.11 GBq), 76% (1.85 GBq), 79% (2.22 GBq), and 81–82% for activities between 2.59 and 3.70 GBq. The therapy activity of 1.11 GBq is considerably less effective than that of 1.85 or 2.22 GBq; therapy activities were equally effective in the range between 2.22 to 3.70 GBq. Conclusion: On the basis of the model and the patients' data included, the lowest effective therapy activity appears to be approximately 2.2 GBq to ablate thyroid remnants. The results of this study may help to guide the design of prospective clinical studies.

Thyroid remnant ablation in differentiated thyroid cancer

2015 ◽  
Vol 36 (11) ◽  
pp. 1100-1106 ◽  
Author(s):  
Alfredo Campennì ◽  
Luca Giovanella ◽  
Salvatore A. Pignata ◽  
Maria A. Violi ◽  
Massimiliano Siracusa ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Thyroid Remnant ◽  
Remnant Ablation

scholarly journals rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review

2005 ◽  
Vol 12 (1) ◽  
pp. 49-64 ◽  
Author(s):  
Markus Luster ◽  
Francesco Lippi ◽  
Barbara Jarzab ◽  
Petros Perros ◽  
Michael Lassmann ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Hormone ◽  
Metastatic Cancer ◽  
Diagnostic Procedures ◽  
Whole Body ◽  
Success Rates ◽  
Thyroid Remnant ◽  
Remnant Ablation ◽  
Thyroid Hormone Withdrawal ◽  
Radioiodine Ablation

Traditionally, withdrawal of thyroid hormone has been used to attain the increase in serum TSH concentrations that are believed to optimize the trapping and retention of radioiodine for diagnostic procedures, thyroid remnant ablation and treatment of patients with differentiated thyroid cancer (DTC). However, withdrawal frequently causes clinical hypothyroidism, with resultant cognitive impairment, emotional dysfunction, physical discomfort, health risks in patients who are elderly, frail or have concomitant illness, and impaired quality of life and ability to work. Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without withdrawal of thyroid hormone and the associated morbidity. rhTSH has been approved as an adjunct for diagnostic procedures in patients with DTC, but is currently an experimental aid in thyroid remnant ablation and the treatment of thyroid tumours. In the period 1997–2004, nearly 30 medical centres worldwide have reported on almost 400 patients with DTC who were given rhTSH in preparation for radioiodine ablation of thyroid remnants or treatment of local tumours of metastatic disease. We have analysed and summarized the findings reported in this literature. Ablation aided by the standard course of rhTSH, two consecutive daily injections of 0.9 mg, had success rates better than 84% in 90 patients given radioiodine activities in excess of 4000 MBq. However, when 1110 MBq was administered, success rates were 81.2% in 16 patients given the standard course of rhTSH and 4-day withdrawal of thyroid hormone around the time of radioiodine administration in one study, but 54% in 70 patients in another study. rhTSH-aided treatment of persistent or recurrent local or metastatic cancer, or both, with from one to six courses of radioiodine 1000–19055 MBq, achieved 2% complete remission, 36% partial response and 27% disease stabilization rates, for a 65% clinical benefit rate, in 115 primarily elderly, late-stage patients for whom responses were reported. Twelve of these patients died as a result of progressive disease or were discharged from hospital into hospice care. Generally, rhTSH was very well tolerated. However, in a minority of patients with central nervous system, spinal or bone metastases, or bulky thyroid remnant or neck lesions with or without poor pulmonary reserve, administration of rhTSH, like thyroid hormone withdrawal, was found to stimulate expansion of the tumour, with ensuing compression of key anatomical structures and neurological, respiratory or other clinical complications. The rapid onset, response to glucocorticoids and radiological findings of peritumoural oedema or, less commonly, haemorrhage in the published cases, strongly suggest that the tumour expansion was the result of swelling rather than growth. As in the case of thyroid hormone withdrawal, special attention and glucocorticoid premedication are thus warranted when rhTSH is given to patients known or suspected to have the above characteristics. Dosimetric data suggest that whole-body and whole-blood radioiodine clearance may be faster in euthyroid patients after administration of rhTSH. In theory, the faster clearance could allow, or demand, increased radioiodine activities when rhTSH is used, but clinical data to date suggest that this may be unnecessary. The faster clearance also might result in safety or convenience benefits with the use of rhTSH, such as decreased exposure of extrathyroid areas to radiation, and shorter hospital stays. In conclusion, in preliminary results from open-label studies, both rhTSH-aided tumour ablation and treatment have been well tolerated and have shown efficacy in substantial proportions of patients. rhTSH-aided ablation merits further study. rhTSH-aided treatment may be preferred in patients who are at greater risk of hypothyroid complications from withdrawal of thyroid hormone or are unable to produce sufficient endogenous TSH, and warrants additional investigation in younger patients at earlier stages of thyroid cancer.

scholarly journals The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer

PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0133852 ◽  
Author(s):  
Aldona Kowalska ◽  
Iwona Pałyga ◽  
Danuta Gąsior-Perczak ◽  
Agnieszka Walczyk ◽  
Tomasz Trybek ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Recombinant Human Tsh
Sign in / Sign up

Export Citation Format

Share Document